Outset Medical (OM) Set to Announce Quarterly Earnings on Wednesday

Outset Medical (NASDAQ:OM) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.64) per share and revenue of $31.40 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The company had revenue of $31.64 million during the quarter, compared to analysts’ expectations of $28.97 million. On average, analysts expect Outset Medical to post ($3.81) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Outset Medical Stock Down 2.3%

OM traded down $0.10 during trading on Wednesday, reaching $4.24. 2,928 shares of the stock were exchanged, compared to its average volume of 345,638. The business’s 50 day moving average price is $3.73 and its two-hundred day moving average price is $4.17. Outset Medical has a 1 year low of $2.84 and a 1 year high of $14.25.

Analyst Ratings Changes

OM has been the subject of a number of research analyst reports. Weiss Ratings cut Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Outset Medical presently has a consensus rating of “Hold” and an average price target of $10.00.

About Outset Medical

Outset Medical, Inc is a medical technology company that develops products for hemodialysis, a treatment that filters waste and excess fluid from the blood when the kidneys are no longer able to do so adequately. The company’s primary product is the Tablo Hemodialysis System, an integrated dialysis platform designed to simplify treatment for healthcare providers and support broader use of dialysis in hospitals, outpatient facilities and the home.

The Tablo system combines dialysis delivery, water purification and dialysate production in a single device and uses a touchscreen interface intended to guide users through treatment setup and operation.